Innovate UK is to invest up to £8 million in collaborative R and D projects to stimulate the development of regenerative medicines and cell therapies in the UK. The aim of this competition is to address the challenges of developing regenerative medicines and cell therapies as clinical treatments and commercial products. They are seeking proposals that advance the development and commercialisation of novel regenerative medicines and cell therapies. The focus is on the preclinical testing, clinical development and manufacture of regenerative medicines and cell therapies, and the development of underpinning tools and technologies. Proposals must be collaborative and led by a business. They expect to fund mainly industrial research projects. Small businesses could receive up to 70% of their eligible project costs, medium-sized businesses 60% and large businesses 50%.
UKRMP Immunomodulation Hub Organisational Profile published in the latest Special Focus Issue of Regenerative Medicine, featuring Hub Partner Paul Fairchild as Guest Editor
Limited funding: The funds for this post are available until 31 January 2018 in the first instance. Three UK Research Councils; Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council and the Medical Research Council have invested £25m in research and equipment to support development of the UK Regenerative Medicine Platform (UKRMP www.ukrmp.org.uk). The Pluripotent Stem Cell Platform (PSCP) is one of five Hubs funded by the UKRMP to tackle critical challenges in developing new regenerative treatments from discoveries made in the laboratory. PSCP brings together researchers from several institutions to develop the processes needed to take pluripotent stem cells from laboratory-based research to the commercial manufacture of safe, effective and reproducible products for use in regenerative medicine.